drugset / Trial / NCT01004861

Safety Study of PLX108-01 in Patients With Solid Tumors

NCT01004861

Phase 1 Completed 132 enrolled Daiichi Sankyo Plexxikon · collab
NaSingle-groupOpen-labelTreatment

Summary

PLX3397 is a selective inhibitor of Fms, Kit, and oncogenic Flt3 activity. The primary objective of this study is to evaluate the safety and pharmacokinetics of orally administered PLX3397 in patients with advanced, incurable, solid tumors in which these target kinases are linked to disease pathophysiology. The secondary objective is to measure the pharmacodynamic activity of PLX3397 via blood, plasma and urine biomarkers of Fms activity.

Timeline

Start
2009-10-01
Primary completion
2018-01-31
Completion
2018-10-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Pexidartinib Small molecule 1000 mg Oral

Indications